PURPOSE: To evaluate abilities of 2-aryl-4-benzoyl-imidazoles (ABI) to overcome multidrug resistance (MDR), define their cellular target, and assess in vivo antimelanoma efficacy. METHODS: MDR cell lines that overexpressed P-glycoprotein, MDR-associated proteins, and breast cancer resistance protein were used to evaluate ABI ability to overcome MDR. Cell cycle analysis, molecular modeling, and microtubule imaging were used to define ABI cellular target. SHO mice bearing A375 human melanoma xenograft were used to evaluate ABI in vivo antitumor activity. B16-F10/C57BL mouse melanoma lung metastasis model was used to test ABI efficacy to inhibit tumor lung metastasis. RESULTS: ABIs showed similar potency to MDR cells compared to matching parent cells. ABIs were identified to target tubulin on the colchicine binding site. After 31 days of treatment, ABI-288 dosed at 25 mg/kg inhibited melanoma tumor growth by 69%; dacarbazine at 60 mg/kg inhibited growth by 52%. ABI-274 dosed at 25 mg/kg showed better lung metastasis inhibition than dacarbazine at 60 mg/kg. CONCLUSIONS: This new class of antimitotic compounds can overcome several clinically important drug resistant mechanisms in vitro and are effective in inhibiting melanoma lung metastasis in vivo, supporting their further development.
PURPOSE: To evaluate abilities of 2-aryl-4-benzoyl-imidazoles (ABI) to overcome multidrug resistance (MDR), define their cellular target, and assess in vivo antimelanoma efficacy. METHODS: MDR cell lines that overexpressed P-glycoprotein, MDR-associated proteins, and breast cancer resistance protein were used to evaluate ABI ability to overcome MDR. Cell cycle analysis, molecular modeling, and microtubule imaging were used to define ABI cellular target. SHO mice bearing A375humanmelanoma xenograft were used to evaluate ABI in vivo antitumor activity. B16-F10/C57BL mousemelanoma lung metastasis model was used to test ABI efficacy to inhibit tumor lung metastasis. RESULTS: ABIs showed similar potency to MDR cells compared to matching parent cells. ABIs were identified to target tubulin on the colchicine binding site. After 31 days of treatment, ABI-288 dosed at 25 mg/kg inhibited melanoma tumor growth by 69%; dacarbazine at 60 mg/kg inhibited growth by 52%. ABI-274 dosed at 25 mg/kg showed better lung metastasis inhibition than dacarbazine at 60 mg/kg. CONCLUSIONS: This new class of antimitotic compounds can overcome several clinically important drug resistant mechanisms in vitro and are effective in inhibiting melanoma lung metastasis in vivo, supporting their further development.
Authors: Jianping Chen; Melissa Smith; Kenneth Kolinsky; Violeta Adames; Nila Mehta; Luke Fritzky; Mohammad Rashed; Eric Wheeldon; Michael Linn; Brian Higgins Journal: Cancer Chemother Pharmacol Date: 2006-08-26 Impact factor: 3.333
Authors: Elizabeth Fox; John M Maris; Brigitte C Widemann; Wendy Goodspeed; Anne Goodwin; Marie Kromplewski; Molly E Fouts; Diane Medina; Susan L Cohn; Andrew Krivoshik; Anne E Hagey; Peter C Adamson; Frank M Balis Journal: Clin Cancer Res Date: 2008-02-15 Impact factor: 12.531
Authors: Souvik Banerjee; Kinsie E Arnst; Yuxi Wang; Gyanendra Kumar; Shanshan Deng; Lei Yang; Guo-Bo Li; Jinliang Yang; Stephen W White; Wei Li; Duane D Miller Journal: J Med Chem Date: 2018-02-12 Impact factor: 7.446
Authors: Min Xiao; Sunjoo Ahn; Jin Wang; Jianjun Chen; Duane D Miller; James T Dalton; Wei Li Journal: J Med Chem Date: 2013-04-09 Impact factor: 7.446
Authors: Shanshan Deng; Raisa I Krutilina; Qinghui Wang; Zongtao Lin; Deanna N Parke; Hilaire C Playa; Hao Chen; Duane D Miller; Tiffany N Seagroves; Wei Li Journal: Mol Cancer Ther Date: 2019-10-23 Impact factor: 6.261
Authors: Vaibhav Mundra; Yang Peng; Virender Kumar; Wei Li; Duane D Miller; Ram I Mahato Journal: Drug Deliv Transl Res Date: 2015-06 Impact factor: 4.617